Proximagen's long-term success is dependent on the introduction of new and innovative therapies.
We recognise that Proximagen is not the only place for great science. Great ideas with the potential to deliver life-changing therapeutics will feed Proximagen’s growth and therefore we look forward to collaborations and M&A activity continuing to play an important role in our pipeline development in 2010 and beyond.
Proximagen is well suited to be the partner of choice in the area of CNS, neuroinflammation/inflammation and oncology having the capabilities and financial strength of a much larger company.